Agios Pharmaceuticals, Inc. (AGIO) down -20.89 per cent in the past week, is under coverage of 8 analysts who collectively recommend a hold rating on stock. 3 of the analysts have a buy or better rating; the 0 sells versus 0 underperforms. The 6 equity analysts who rate the stock have an average target price at $62.33, with individual targets ranging between $46 and $90. The shares closed last trade at $48.75, implying that analysts see shares rising about 27.86 per cent in 12 months’ time.
Insider Activity: Insiders look pessimistic about the prospects of the company that they seem to offload shares while they are -24.91 down so far this year. A Chief Scientific Officer at Agios Pharmaceuticals, Inc. (AGIO) sold shares in the company in a transaction completed on Wednesday June 08, 2016. Biller Scott offloaded 27,500 shares in the company at an average price of $65 and ended up generating $1,787,500 in proceeds. Biller Scott retains 74,270 shares in the company after this transaction. A Director in the company, Cantley Lewis Clayton Jr., on Thursday May 26, 2016 collected $129,430 from the sale of 2,504 shares at $65 each. Insiders are expected to know better about the health and prospects of their company, which is why insiders’ move deserves attention.
Earnings to Watch: Investors considering AGIO stock at the going market price of $48.75/share should know the stock will next release quarterly results for the June 2016 quarter. For the reporting quarter, analysts expect the company to deliver -$0.48 in earnings per share (EPS). That would represent a -43.53% year-over-year decrease. Revenue for the same period is expected to arrive at $39.62M.
Earnings Roundup: In the last fiscal quarter alone, Agios Pharmaceuticals, Inc. generated around $31.28M in revenue and net income of -$0.61/share. That compares with the consensus estimate $20.94M and -$0.79/share, respectively. For the prior quarter revenue for the company hit $6.22M, with earnings at -$1.08/share.
Analyst Coverage: JP Morgan has been a brokerage house following shares of Agios Pharmaceuticals, Inc. (AGIO), so its rating change is noteworthy. The stock was upgraded to Overweight from Neutral, wrote analysts at JP Morgan, in a note issued to clients on Monday June 13, 2016. There was another key note issued by Sun Trust Rbsn Humphrey on Wednesday March 30, 2016. The firm launched coverage on AGIO at Buy.
Price Momentum: Despite the -6.2% decrease in value, the stock’s new closing price represents a -59.7% fall in value from company’s one year high of $120.96. The stock is currently holding above its 50 day moving average of $-3.16 and below its 200 day moving average of $51.03. Over the last three months and over the last six months, the shares of Agios Pharmaceuticals, Inc. (AGIO), have changed -14.82% and 48.34%, respectively.